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ecent experimental and clinical retrospective studies
support the view that reduction of brain cholesterol
protects against Alzheimer’s disease (AD). How-
ever, genetic and pharmacological evidence indicates
that low brain cholesterol leads to neurodegeneration.
This apparent contradiction prompted us to analyze the
role of neuronal cholesterol in amyloid peptide generation
in experimental systems that closely resemble physiological
and pathological situations. We show that, in the hippo-
campus of control human and transgenic mice, only a
small pool of endogenous APP and its 
 
 
 
-secretase, BACE 1,
R
 
are found in the same membrane environment. Much
higher levels of BACE 1–APP colocalization is found in
hippocampal membranes from AD patients or in rodent
hippocampal neurons with a moderate reduction of
membrane cholesterol. Their increased colocalization is
associated with elevated production of amyloid peptide.
These results suggest that loss of neuronal membrane
cholesterol contributes to excessive amyloidogenesis in
AD and pave the way for the identiﬁcation of the cause
of cholesterol loss and for the development of speciﬁc
therapeutic strategies.
 
Introduction
 
A large body of evidence indicates that changes in cholesterol
homeostasis affect APP metabolism. More than a decade ago
Roses and colleagues (Corder et al., 1993) demonstrated the
existence of a genetic link between the risk of AD and the 
 
 
 
4
allele of apolipoprotein E, a protein involved in cholesterol
homeostasis (Myers and Goate, 2001). In cells in culture,
overexpressed APP and its 
 
 
 
 and 
 
 
 
 cleaving enzymes have
been found in cholesterol-rich regions of cell membranes,
known as detergent-resistant membrane (DRM) microdomains
or rafts (Burns and Duff, 2002; Ehehalt et al., 2003). In agree-
ment with such colocalization having a functional relevance,
treatment of these cells with cholesterol synthesis inhibitors
and membrane cholesterol extracting drugs results in a drastic
reduction of A
 
 
 
 production (Simons et al., 1998; Fassbender
et al., 2001; Ehehalt et al., 2003). These studies have led to
the view that the principal site of A
 
 
 
 production in the cell are
the cholesterol rich membrane areas and that high brain choles-
terol can contribute to AD by increasing the number of sites
where A
 
 
 
 generation can occur. This conclusion is supported
by retrospective clinical studies showing that people with
high blood-cholesterol levels treated with the cholesterol-
lowering drugs statins present a reduced incidence of AD
(Jick et al., 2000; Wolozin et al., 2000; Austen et al., 2002).
Contrary to the above view, in vivo evidence implies that
lowering brain cholesterol can lead to AD. Rodents treated with
the cholesterol-synthesis inhibitor lovastatin, the statin that is
most permeable to the blood brain barrier, have increased amy-
loid production and senile plaque deposition (Park et al., 2003).
Moreover, A
 
 
 
 aggregation has been also found in Niemann
Pick disease type C (Burns and Duff, 2002), a disorder charac-
terized by the accumulation of cholesterol in late endosomes
and lysosomes and a reduction of cholesterol on the axonal
membrane (Karten et al., 2002). In the genetic disorder
known as RSH/Smith-Lemli-Opitz syndrome, an accumula-
tion of 7-dehydrocholesterol and a paucity of cholesterol cause
severe neurodegeneration and early death (Porter, 2000). The
altered gene in this disease, which is responsible for the con-
version of 7-dehydrocholesterol into cholesterol, is homolo-
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gous to seladin-1, which is abnormally down-regulated in the
neurons of AD patients in areas of the brain showing the high-
est levels of amyloid deposition (Greeve et al., 2000; Iivonen et
al., 2002). This finding is consistent with the recent observation
that the hippocampus of certain AD patients present a moderate,
yet significant, reduction in membrane cholesterol (Ledesma et
al., 2003). The precise role of neuronal membrane cholesterol
in A
 
 
 
 peptide production in the physiological scenario of con-
stitutive protein expression in neuronal cells therefore remains
to be determined.
 
Results
 
Endogenous BACE 1 and APP 
copartition in detergent-soluble 
membrane fractions of human and rodent 
brain membranes
 
To determine the possible involvement of membrane choles-
terol in APP processing in physiological conditions, we
started by analyzing the buoyant flotation density of this pro-
tein and that of its 
 
 
 
-secretase BACE 1 in human brain hip-
pocampal membranes. Sucrose gradient centrifugation of
membranes extracted with the detergents Lubrol, CHAPS, or
Triton X-100, followed by SDS-PAGE and Western blotting
with NH
 
2
 
 terminus antibody (see Materials and methods), re-
vealed that most APP is in heavy, detergent-soluble mem-
brane fractions (Fig. 1 A; Fig. S1, available at http://www.jcb.org/
cgi/content/full/jcb.200404149/DC1). By contrast, a signifi-
cant amount of BACE 1 is also present in light, detergent-
resistant fractions, similarly to the DRM marker flotilin 1
(Fig. 1 A). The existence of a pool of BACE 1 in DRMs and
another in non-DRMs, similarly to other canonical DRM
markers (Fig. S2, available at http://www.jcb.org/cgi/content/
full/jcb.200404149/DC1), confirms that the protein is in a dy-
namic balance on the membrane. On the other hand, the al-
most complete absence of APP in DRMs suggests that this
protein is largely restricted to the most fluid environment of
non-DRMs.
To establish if endogenous APP is undetected in DRMs
because of true natural low cholesterol-partitioning affinity or
because of secondary events that affected its biochemical char-
acteristics, i.e., due to the conservation process, age or associ-
ated diseases, the flotation density of APP was analyzed in
freshly prepared hippocampal membranes from human APP
transgenic mice, that express moderate levels of the protein
without plaque or tangle pathology (Mucke et al., 2000). The
results obtained were similar to those with the human mem-
branes: APP is present in heavy fractions and undetectable in
DRMs (Fig. 1 B).
To rule out that APP is undetected in DRMs because of
the low concentration in our preparation of membranes from
Golgi stacks or endosomes, that have been postulated as the
sites where 
 
 
 
-cleavage takes place (Xu et al., 1997; Daugherty
and Green, 2001) membranes from these organelles were puri-
fied from hAPP mice brains (see Materials and methods). As
with the total membrane extract only a significant pool of
BACE 1, but not APP, is present in DRMs (Fig. 1 C).
Considering that a pool of APP has been reported to par-
tition in DRMs in a number of cell types under overexpression
conditions (Ehehalt et al., 2003), we analyzed if increasing
APP levels in neurons would suffice for its incorporation into
these domains. Thus, human APP was expressed transiently via
the Semliki Forest virus vector (De Strooper et al., 1995) in
pseudo-neuronal and primary neurons in culture. Fig. 2 A
shows that only a small percentage of the protein is in DRMs
(
 
 
 
5%) in overexpressing undifferentiated N2A rodent neuro-
blastoma cells. On the other hand, APP remains undetectable in
DRMs of both overexpressing SH-SY5Y human neuroblas-
toma cells and rat hippocampal neurons in primary culture
(Fig. 2, B–D).
Together, these first series of results point in the direction
that non-DRM domains of brain cells are the preferred sites for
the interaction between BACE 1 and its substratum APP.
Figure 1. BACE 1 floats in the DRM fraction from control human and mice
brain membranes, whereas APP remains in non-DRM heavy fractions.
(A) Immunoblots for APP, BACE 1, and flotilin1 in a representative control
human  hippocampal sample after Lubrol WX extraction and sucrose
gradient centrifugation. Note that BACE 1 is enriched in fractions 4 and 5
corresponding to DRMs as indicated by the presence of the DRM marker
flotilin 1 (Flot-1). APP, on the contrary, is only detected in heavy fraction 8.
The percentages of total BACE 1 in DRMs and fraction 8 are shown in the
graph as means and SDs from 10 control human samples. (B) Immunoblots
for APP, BACE 1, and flotilin 1 of hippocampal extracts from mice ex-
pressing the human APP after Lubrol WX extraction and sucrose gradient
centrifugation. As for the human brain, BACE 1 is enriched in fractions 4
and 5 corresponding to DRMs as indicated by the presence of the DRM
marker flotilin1 (Flot-1), whereas APP is only detected in heavy fraction 8.
(C) Immunoblots for APP, BACE 1, and flotilin 1 of Golgi-endosomal–
enriched brain membranes from mice expressing the human APP after
Lubrol WX extraction and sucrose gradient centrifugation. Although BACE
1 floats to DRM light fractions similar to flotilin 1, APP remains in the
heavy fractions of the gradient. 
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A minor pool of BACE 1 and APP 
colocalize on the surface of hippocampal 
neurons in culture
 
Because differences in detergent partitioning cannot be used
as the sole parameter to conclude that a given protein is
present or excluded from a particular domain of the membrane
(Zurzolo et al., 2003), we investigated next the distribution of
endogenous APP and BACE 1 on the plasma membrane of
living neurons in culture. Thus, antibody “copatching” (Harder
et al., 1998; Ehehalt et al., 2003) for these molecules was per-
formed in live rodent hippocampal neurons in culture (see
Materials and methods). This work revealed that only 7% of
APP positive dots exactly colocalize with BACE 1 clusters
(Fig. 3 B; Fig. 5 for details and quantitation; Fig. S3, available
at http://www.jcb.org/cgi/content/full/jcb.200404149/DC1). Be-
cause APP is not detected in DRMs by biochemistry (Fig. 1),
it is quite likely that the few coclusters revealed in the micros-
copy assay reflect non-DRM coexistence. Further confirming
the biochemical differences, a large proportion of BACE 1 on
the neuronal surface is in DRMs, as judged from the extensive
copatching with Thy-1 (Fig. 3 A). Together, with the previ-
ously demonstrated paucity of APP in the DRMs of Golgi and
endosomal membranes (Fig. 1 C), this first series of results is
Figure 2. Overexpression of human APP leads to the incorporation of the
protein in DRMs from rodent neuroblastoma N2A cells but not in human neu-
roblastoma SH-SY5Y cells or rat hippocampal neurons in primary culture.
Nondifferentiated N2A cells (A), nondifferentiated SH-SY5Y cells (B) and
mature primary rat hippocampal neurons (C) were infected with SFV-APP for
8 h. Cell extracts were detergent extracted at 4 C and centrifuged in sucrose
gradients. DRMs were obtained in fractions 4 and 5 as indicated by the en-
richment of the DRM marker flotilin1. Although a small amount of human
APP ( 5%) appears in DRMs from overexpressing N2A cells, no significant
amount of the protein was found in the DRM fractions from SH-SY5Y or pri-
mary neurons even when the levels of APP overexpression are very high
(see fractions 7 and 8 of the gradients). The absence of overexpressed APP
in detergent insoluble membranes of primary hippocampal neurons was fur-
ther confirmed along the biosynthetic pathway with a pulse-chase experi-
ment after metabolic labeling (D). Mature neurons were infected either with
Fowl plague virus to express the DRM marker HA (D, a) or with SFV-APP (D,
b) and extracted with 20 mM CHAPS at 4 C. CHAPS-soluble material (S)
and insoluble (P) was resolved in SDS-PAGE (6%) and the images obtained
by autoradiography. Although HA CHAPS insolubility increases during the
biosynthetic pathway (D, a) and is evident after 90-min chase, when the pro-
tein has already reached the plasma membrane, APP remains CHAPS solu-
ble along the biosynthetic pathway and transport to the membrane (D, b).
Figure 3. BACE 1 copatches with the DRM marker Thy-1 but is largely
segregated from APP in the neuronal plasma membrane. Hippocampal neu-
rons were cultured for 10 d and pairs of membrane proteins were studied
by the copatching technique (see Materials and methods). (A) BACE 1 and
the DRM marker Thy-1 copatch extensively, indicating that both molecules
are located in membrane DRM domains (note yellow dots in the enlarged
images). (B) APP and BACE 1, in contrast, appear extensively segregated. 
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consistent with the view that non-DRM domains of the plasma
or internal membranes are the preferred sites for BACE 1–APP
interaction.
 
APP and BACE 1 biochemical and spatial 
association is enhanced in conditions of 
low membrane cholesterol
 
To determine if the cleavage of APP can be affected by
changes in membrane cholesterol content we analyzed the flo-
tation density of BACE 1 and APP in hippocampal membranes
from the brains of a group of AD patients that present a moder-
ate, still significant, reduction of brain membrane cholesterol
(30% less than controls; Ledesma et al., 2003). Fig. 4 A shows
that in these membranes APP remains concentrated in deter-
gent-soluble fractions, like in the control situation. Quite dif-
ferently from controls, BACE 1 is significantly reduced from
the light detergent-resistant fractions and increased in the solu-
ble fractions (Fig. 4 A, compare the partitioning profile of both
proteins with Fig. 1 A). Densitometric quantification reveals
that in the low cholesterol membranes there is a 50% increase
(P 
 
  
 
0.005) in the amount of BACE 1 present in the soluble
fractions where APP also concentrates (compare Fig. 1 A with
Fig. 4 A). The fact that the total amount of BACE 1, measuring
both insoluble and soluble fractions, is similar in low choles-
terol AD samples and controls, indicates that the loss of BACE
1 from DRMs is not the consequence of changes in its rates of
synthesis or degradation but results from a change in DRM or-
ganization. In agreement, a significant pool of flotilin 1 is dis-
placed to the soluble fractions in the low cholesterol human
membranes (Fig. 4 A).
To determine if BACE 1 reduction from DRM in the low
cholesterol human membranes is the direct consequence of
cholesterol loss, we studied the partitioning characteristics of
BACE 1 and APP in rodent hippocampal neurons in culture in-
duced to lose 30% of membrane cholesterol (Ledesma et al.,
2003), similar to the constitutive loss of the AD membranes.
Identical to the human membranes, moderate membrane cho-
lesterol reduction in rodent neurons results in a significant loss
of BACE 1 from DRMs, and increase in the soluble, APP-con-
taining fractions (Fig. 4 B).
To test whether enhanced BACE 1–APP copartitioning
due to cholesterol reduction results in higher spatial associa-
tion, living hippocampal neurons with low and normal choles-
terol membrane levels (see Materials and methods; Ledesma
et al., 2003), were incubated with specific antibodies and the
pattern of colocalization analyzed by immunofluorescence mi-
croscopy (Fig. 5, A and B; Fig. S3). Quantitative analysis
showed that in low cholesterol neurons 18% of APP clusters
colocalize completely with those containing BACE 1, whereas
an additional 21% of APP positive areas partially colocalize
(Fig. 5 C). In cells with normal-cholesterol levels only 7%
completely copatch and 12% partially copatch (P 
 
  
 
0.005).
The enhanced colocalization cannot be attributed to membrane
shrinkage, due to the reduction of cholesterol, as clusters of
the non-DRM membrane protein transferrin receptor remain
segregated from those of APP or BACE 1 (unpublished data).
Although antibody incubation is performed at low tempera-
ture, that should prevent internalization, we cannot rule out
that some of the APP–BACE 1 coclusters observed in the low
cholesterol samples occur in early endosomes. In any event,
whether surface or endosomal, the fact that higher BACE 1
and APP colocalize in low cholesterol membranes moved us
to test how this condition would affect APP 
 
 
 
-cleavage.
 
Moderate cholesterol loss enhances APP 
 
 
 
-cleavage and amyloid peptide 
production
 
To determine whether the enhanced biochemical and spatial as-
sociation between BACE 1 and APP resulting from moderate
cholesterol reduction is functionally relevant, the production of
the 
 
 
 
-COOH-terminal fragment (
 
 
 
-CTF) of APP and of A
 
 
 
was measured in APP constitutively expressing hippocampal
neurons and in APP stably transfected fibroblast-like cells
(CHO) in culture, with normal or a moderate to high membrane
Figure 4. BACE 1 is displaced from DRMs and cofractionates with APP in
heavier membrane fractions of low membrane cholesterol AD hippocampi
and hippocampal neurons in culture. (A) Immunoblots for APP, BACE 1,
and flotilin1 in representative low membrane cholesterol AD hippo-
campal sample after Lubrol WX extraction and sucrose gradient centrifu-
gation. Note that BACE 1 migration is shifted to the heavy APP-containing
fraction 8. DRM modification is shown by a similar shift in the flotation
characteristics of the DRM marker flotilin 1 (compare with Fig. 1 A). For
quantification, the amount of BACE 1 in fractions 4 and 5 of sucrose gra-
dients (DRM fraction) and fraction 8 (heavy APP-containing fraction) was
measured by densitometry. The percentage of BACE 1 in DRMs is signifi-
cantly reduced to 14% (graph, * indicates P   0.005) compared with
24% in control samples (Fig. 1 A, graph). Conversely in the APP-contain-
ing fraction 8 BACE 1 content is increased to 15% compared with 10%
in control samples (Fig. 1 A, graph). Data are means and SDs from 10
low cholesterol AD samples. (B) Moderate membrane cholesterol reduction
in vitro displaces BACE 1 from DRMs. Hippocampal neurons grown for 5 d
in culture were treated (low chol.) or not (control) with low concentrations
of mevilonin and MCD for 5 d (see Materials and methods). This treat-
ment induced  30% reduction in membrane cholesterol. Sucrose gradient
fractionations after Lubrol WX extraction and Western blotting for APP
and BACE 1 show that in control neurons BACE 1 peaks in fractions 4
and 5 (DRMs), whereas in low cholesterol neurons BACE 1 is spread along
the gradient, with a relative enrichment in the APP-containing fraction 8.
Disruption of DRMs is shown by the almost complete absence of flotilin 1
in fractions 4 and 5 and the relative enrichment in heavy fraction 8
(compare Flot-1 lines in control and low chol. samples). 
NEURONAL CHOLESTEROL MODULATES BACE 1–APP INTERACTION • ABAD-RODRIGUEZ ET AL.
 
957
 
cholesterol reduction. The level of 
 
 
 
-CTF in hippocampal neu-
rons with a 25–30% reduction of membrane cholesterol is 39%
higher than in cells with normal membrane cholesterol content
(P 
 
  
 
0.005; Fig. 6 A). To test if the increased production is the
direct consequence of the loss of cholesterol different from a
secondary, unspecific effect of the added drugs, cholesterol
was replenished to the treated neurons in the form of cyclodex-
trin–cholesterol inclusion complexes (Simons et al., 1998).
Such treatment for 15 min restores membrane cholesterol lev-
els (110% of control). Notably, the level of APP 
 
 
 
-cleavage in
this condition is reestablished to the nontreated situation (91%
of control; Fig. 6 A).
To confirm that mild reduction of membrane choles-
terol leading to higher 
 
 
 
 cleavage results in higher A
 
 
 
 pro-
duction, the amount of peptide was measured in low and
normal membrane cholesterol CHO cells constitutively
expressing human APP. These cells were chosen because
they release much more peptide into the medium than the pri-
mary neurons, still APP is confined to non-DRM domains
(Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200404149/DC1), like in the hippocampal neurons. In
CHO cells, membrane cholesterol reduction of 
 
 
 
25% results
in a significant increase in the amount of peptide into the me-
dium 47%, Fig. 6 B compared with cells with normal mem-
brane cholesterol levels. This is paralleled by an increase in
the production of 
 
 
 
-CTF (30.6%). Contrary to the mild cho-
lesterol loss situation, cells with a reduction of 
 
 
 
35% of
membrane cholesterol release less A
 
 
 
 than control cells (Fig.
6 B). This last effect is most likely due to overall disruption
of membrane integrity.
 
Discussion
 
The demonstration that in neuronal cells both APP and BACE
1 colocalize in the more fluid areas of membranes, as judged
from detergent-solubility criteria, strongly indicates that a fluid
milieu offers the optimal conditions for enzyme–substratum in-
teraction. This finding is supported by the observation that APP
is largely, if not fully, excluded from the less fluid cholesterol-
rich DRMs. Future work is needed to define whether the fluid
membrane domains where 
 
 
 
-cleavage occurs are those of the
plasma membrane or of the Golgi and endosomes, which have
been postulated as preferred cleavage sites (Xu et al., 1997;
Daugherty and Green, 2001).
The above scenario raises the question of the role
played by BACE 1 in the cholesterol-rich membrane do-
mains. One possibility is that this pool of BACE 1 is in-
volved in the cleavage of substrates other than APP (Kita-
zume et al., 2003). Alternatively, BACE 1 in DRMs may
cleave the few APP molecules that gain access to such envi-
ronment. Although the latter scenario cannot be ruled out, a
number of results indicate that it is unlikely. First, APP in
neurons does not seem to have the capacity to become incor-
porated into cholesterol-rich environments, even at high ex-
pression levels (Fig. 2). Second, and most relevant, treat-
ments leading to a moderate reduction of neuronal cholesterol
result in increased cleavage, which is inconsistent with the
occurrence of BACE 1 cleavage of APP in cholesterol-rich
territories. Thus, BACE 1 in cholesterol-rich domains may
represent an inactive pool of the protein, at least in terms of
APP cleavage, which can be delivered when required to sol-
uble domains where APP resides. In support of this view, a
mild reduction of membrane cholesterol results in more
BACE 1 in the soluble fractions, higher BACE 1–APP colo-
Figure 5. Moderate cholesterol reduction induces coclustering of BACE 1
and APP on the plasma membrane of cultured hippocampal neurons.
BACE 1–APP colocalization was studied in 10 d in vitro hippocampal
neurons using the copatching technique (see Materials and methods).
(A) In control neurons BACE 1 (red clusters) and APP (green clusters) are
extensively segregated to different membrane domains. (B) In contrast,
low cholesterol neurons (treated as indicated in Materials and methods to
lower the membrane cholesterol up to 30%) show a clear enhancement of
BACE 1–APP colocalization. (C) For quantification, the degree of intersec-
tion among APP and BACE 1 clusters was considered as “copatching”
(intersection  80%), “partial copatching” (intersection between 30% and
50%),“contact” (intersection between 0% and 30%), or random (no inter-
section; not depicted). For control cells 7% of APP clusters copatch and
12% partially copatch with BACE 1 (gray bars). These values are signifi-
cantly increased to 19% and 21%, respectively (* indicates P   0.005)
in low cholesterol neurons (black bars). Data are means and SDs of three
independent experiments. 
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calization and enhanced 
 
 
 
 processing. We observed that
 
 
 
-processing returns to control values when cholesterol is
added back. Given this evidence, it is reasonable to postu-
late that neuronal cholesterol-rich membrane domains, and
thus cholesterol, directly affect APP cleavage efficacy by
acting as membrane “basins” from which BACE 1 can exit
or enter to initiate or arrest, respectively, APP cleavage in
nearby domains.
Our data and conclusions contradict previous work in
which acute and drastic reduction of membrane cholesterol
resulted in decreased amyloid production (Simons et al.,
1998; Fassbender et al., 2001; Ehehalt et al., 2003). One ex-
planation for the discrepancy is that these previous results
were obtained using cells that overexpress APP and thus have
higher amounts of the protein in DRMs. Because endogenous
BACE 1 is present in DRMs, “addition” of APP into these do-
mains by means of overexpression may increase 
 
 
 
 cleavage in
a cholesterol-dependent manner. Alternatively, in the overex-
pressing cells more cleavage may have occurred as a result of
excess APP in non-DRM domains, an event that could cer-
tainly be affected by a drastic cholesterol reduction, as we
have now shown.
Based on the observation that overexpression of a GPI-
form of BACE 1 in undifferentiated pseudo-neuronal cells
(SH-SY5Y) enhances amyloid production, and that this is
blocked by membrane cholesterol depletion, Cordy and col-
leagues (Cordy et al., 2003) suggested that BACE 1 cleaves
APP within DRMs. However, the fact that a significant
amount of overexpressed GPI-BACE 1 is present in non-
DRMs is equally consistent with the cleavage of APP hav-
ing taken place in such domains. This interpretation is sup-
ported by the authors’ demonstration that cholesterol reduc-
tion also decreases A
 
 
 
 production in cells that overexpress
the non-GPI form of BACE 1 and by our demonstration that
the cells used in the work, SH-SY5Y, have little, if any, ca-
pacity to include APP in DRMs, even after overexpression
(Fig. 2).
Our data, together with genetic evidence (Introduc-
tion), imply that lowering CNS cholesterol would be delete-
rious to neuronal function. Paradoxically, chronic treatments
with cholesterol-reducing statins currently in clinical use
have been shown to prevent AD (Jick et al., 2000; Wolozin
et al., 2000). The most commonly used statins, however, do
not penetrate the CNS significantly (Sparks et al., 2002),
and neither patients nor experimental animals treated with
statins show major changes in brain membrane cholesterol
(Fassbender et al., 2001); only circulating cholesterol is
lowered. Thus, it is unlikely that these drugs prevent AD by
reducing neuronal membrane cholesterol. The preventive ef-
fects of these drugs may be due to their well-known antioxi-
dant and anti-inflammatory properties (Cucchiara and Kas-
ner, 2001; Zamvil and Steinman, 2002) or to the improvement
of brain oxygenation secondary to low peripheral choles-
terol levels. Care should be taken not to administer to pa-
tients statins that can cross the blood-brain barrier and di-
rectly inhibit cholesterol synthesis in brain cells, as one
likely consequence may be the perturbation of the numerous
physiological functions performed in cholesterol-rich mem-
brane areas, including the restriction of APP cleavage. There-
fore, we find it necessary to develop drugs to prevent neu-
ronal cholesterol loss. Simultaneously, we need to learn
more about the causes of such deficit.
Figure 6. Moderate membrane cholesterol reduction
in vitro enhances APP- -cleavage and A  production.
(A) 10 d in vitro hippocampal neurons were not treated
(C) or treated as indicated in Materials and methods to
lower the membrane cholesterol up to 30% (Chol ). Cho-
lesterol was added back to some of the treated cells for
15 min (Chol ) as cholesterol–MCD inclusion complexes.
The amount of total APP and APP- -CTF fragment in the
different cell extracts was determined by Western blot.
Densitometry of the  -CTF fragment normalized to the
amount of total APP revealed a significant 39% increase
in low cholesterol neurons with respect to untreated neu-
rons. This effect was reverted by cholesterol replenishment.
Thus, a 15-min treatment with the cholesterol inclusion
complexes results in the production of similar amount of
 -CTF fragment than control neurons (91% of control).
Data shown in the graph are means and SDs from three
different experiments. (B) Crude membrane pellets and
conditioned media of control or low membrane cholesterol
CHO-7w cells (stably expressing human APP) were sub-
mitted to PAGE-SDS in 10% Bis-Tris NuPage gels. Western
blot detection was performed with an anti-APP COOH-
terminal antibody to visualize holo-APP and with anti-APP
mAb (WO2) to detect the amyloid peptide. A  peptide
production was increased in cases of moderate low
cholesterol an average of 47% over the control (lanes 1
and 3 in the blot and  25% bar in the graph, n   6).
Confirming previous data from other groups, extensive
cholesterol loss over 35% leads to a strong decrease in
A  production (lane 2 in the blot and  35% bar in the
graph, n   2). 
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Materials and methods
 
Cell culture
 
Primary cultures of rat embryo hippocampal neurons were prepared as de-
scribed previously (Goslin, 1991). For biochemical analysis, 100,000 cells
were plated onto 3-cm plastic dishes coated with poly-
 
L
 
-lysine (0.1 mg/ml)
and containing MEM with N2 supplements. For morphological studies,
150,000 cells were plated onto poly-
 
L
 
-lysine glass coverslips in 6-cm dishes
containing MEM with N2 supplements. Neurons were kept under 5% CO
 
2
 
at 36.5
 
 
 
C.
 
Human brain samples
 
Samples correspond to the hippocampus of 10 control brains and 10 AD
brains with the 4 allele of apolipoprotein E and low levels of membrane
cholesterol (Ledesma et al., 2003). The samples had mean ages 87 
 
 
 
 11
and 79 
 
 
 
 6 yr old, respectively. Postmortem delays were ranging from 5
to 25 h and the causes of death were variable. The following parameters
were analyzed as described by Delacourte (2001): Braak stage for neu-
rofibrillary tangles ranged from stage 0 to stage III in controls and from
stage IV to VI in AD samples. Braak stage for amyloid deposition varied
from stage 0 to stage A in controls, whereas AD samples showed stage B
in one case and the rest were stage C. The amount of A
 
 
 
 42 deposition in
the hippocampus was 0–34 
 
 
 
g/g for control brains and 130–412 
 
 
 
g/g
for AD brains. The clinical dementia rating scored 0–0.5 in control indi-
viduals and 3 for all AD cases except for one, which showed 0.5. Finally,
the mean duration of dementia was 8.6 
 
 
 
 3.9 yr for AD brains.
 
Mice expressing human APP
 
Mice expressing wild-type human APP (Mucke et al., 2000) were donated
by L. Mucke (University of California, San Francisco, San Francisco, CA).
These mice express moderate levels of human APP in neurons that do not
result in the formation of amyloid plaques.
 
Total and membrane hippocampal extracts
 
Human or mice hippocampal tissues were homogenized in PBS containing
9% sucrose and protease inhibitors (CLAP: pepstatin, antipain, chymosta-
tin, each at a final concentration of 25 
 
 
 
g/ml) using a dounce homoge-
nizer and 10 passages through a 22-gauge syringe. The samples were
centrifuged for 10 min at 2,500 rpm and the supernatants were consid-
ered as total extracts. A further centrifugation was performed at 100,000 
 
g
 
for 1 h at 4
 
 
 
C to pellet the membrane fraction. Protein concentration was
quantified by the BCA method (Bio-Rad Laboratories).
 
Preparation of Golgi-endosomal–enriched membranes
 
Golgi-endosomal membranes were isolated from total mice brain as de-
scribed previously (Fath and Burgess, 1993) with several modifications.
Total brains were homogenized in ice-cold 0.5 M sucrose-PKM buffer
(100 mM potassium phosphate, pH 6.5, 5 mM MgCl
 
2
 
, and 3 mM KCl)
with a hand-held tissue grinder. Samples were centrifuged for 10 min at
2,500 rpm. The postnuclear supernatant was centrifuged again two more
times for 10 min at 8,000 rpm each to get a lysosomal and mitochondrial-
free fraction. The last supernatant was layered onto a step gradient con-
taining 1.3 M sucrose-PKM and 0.7 M sucrose-PKM, then centrifuged at
17,500 rpm in a SW40 rotor for 60 min. Membranes that concentrated at
the 0.7/1.3 sucrose interface were collected and adjusted to 1.25 M su-
crose-PKM. The membranes were overlaid with 1.1 M sucrose-PKM, 0.5 M
sucrose-PKM, and centrifuged at 15,000 rpm in a SW40 rotor for 90 min.
Golgi-endosomal membranes were collected at the 0.5/1.1 M interface.
 
DRM isolation on sucrose gradients
 
Hippocampal samples (100 
 
 
 
g of total protein) or membrane pellets from
cell cultures were extracted in MBS buffer (25 mM MES, 150 mM NaCl,
pH 6.5) containing CLAP and 1% Lubrol WX (Serva), 1% Triton X-100 or
20 mM CHAPS, depending on the experiment. After 60 min of incubation
at 4
 
 
 
C, the suspensions were brought to 60% sucrose in MBS and a su-
crose step gradient was overlaid (35% and 5% sucrose). After centrifuga-
tion at 35,000 rpm for 18 h at 4
 
 
 
C, fractions were collected from the top
of each tube. Fractions 4–5 were identified as the raft fraction by the pres-
ence of the raft marker flotilin 1 in the control samples.
 
Viral infection and metabolic labeling
Nondifferentiated N2A and SH-SY5Y cell lines and primary rat hippo-
campal neurons were infected for 8 h with Semliki Forest virus/human
APP (SFV-APP; De Strooper et al., 1995) and extracted for 1 h at 4 C in
20 mM CHAPS before sucrose gradient fractionation. For metabolic label-
ing experiments, hippocampal neurons were infected with Fowl plague vi-
rus or SFV-APP for 8 h and pulse labeled during 30 or 10 min, respec-
tively, with 
35S-methionine (200  Ci/ml). The cells were chased in fresh
medium for 0–90 min as indicated.
Partial membrane cholesterol reduction and conditioned media 
preparation
For low membrane cholesterol experiments 5 d in vitro hippocampal neu-
rons were treated with 0.4  M mevilonin and 0.5 mM methyl- -cyclodex-
trin (MCD) and the cells were processed at day 10. CHO-7w cells were
treated during 48 h with 0.4  M mevilonin and 1 mM MCD for moder-
ate cholesterol loss ( 25%) or with 0.4  M mevilonin and 1.5 mM MCD
for high cholesterol loss ( 35%). Cells were scraped with PBS-CLAP at
4 C, lysed by sonication, and centrifuged at 1,000 g. Postnuclear super-
natants were further centrifuged at 100,000 g, 1 h at 4 C to get the
membrane pellet. After resuspension in PBS-CLAP 0.1% Triton X-100, pro-
tein and cholesterol concentrations were measured. Conditioned media
were prepared by incubating the cultured cells with Locke’s solution for
8 h in 5% CO2 at 36.5 C.
Cholesterol–MCD inclusion complexes
Cholesterol–MCD inclusion complexes were prepared as described previ-
ously (Klein et al., 1995). These complexes containing 0.3 mM com-
plexed cholesterol were added to the medium at a final 1:10 dilution to-
gether with 2  g/ml free cholesterol to neurons treated with mevilonin
and MCD as described above.
Cholesterol determination
We measure total cholesterol in samples containing equal amount of pro-
tein using Ecoline 25 (Merck). Ecoline relies on the enzymatic oxidation
by cholesterol oxidase, producing H2O2. This is converted into a colored
quinonimine in a reaction with 4-aminoantipyrine and salicylic alcohol
catalyzed by peroxidase. The OD was measured at 500 nm and we used
pure cholesterol (Sigma-Aldrich) solutions as standards.
Antibodies, Western blots, quantification, and statistical analysis
Sucrose gradient fractions were submitted to 10% PAGE-SDS electro-
phoresis and probed with monoclonal anti-APP (clone 22C11; Roche),
monoclonal anti-flotilin 1 (clone 18; Transduction Laboratories), and poly-
clonal chicken anti-BACE 1 (raised against Fc-Asp 2-fusion protein). The
specificity of the antibody was controlled by both Western blotting and im-
munohistochemistry in samples from BACE 1 knockout mice (Riddell et al.,
2001). Species-specific peroxidase-conjugated secondary antibodies and
the ECL method (Amersham Biosciences) were subsequently used. Quanti-
fication was done by densitometry of the autoradiograms using the NIH-
image software. Results were checked with t test and P values  0.005
were considered statistically significant.
Quantification of peptides from APP cleavage
Cell pellets from mature cultured hippocampal neurons (control, low cho-
lesterol, or replenished cholesterol) were submitted to 8–15% gradient
PAGE-SDS, transferred to nitrocellulose, and blotted with monoclonal anti-
APP (clone 6E10; Sigma-Aldrich) for  -CTF.
Crude membrane pellets of control CHO-7w cells (stably expressing
human APP) and CHO-7w cells treated to lower membrane cholesterol,
were resuspended in 0.2% SDS. 30  g of these membrane extracts were
applied on a 10% Bis-Tris NuPage gel (Invitrogen) using MES as running
buffer and transferred to nitrocellulose membrane. Western blot detection
was performed with an anti-APP COOH-terminal antibody (B63.1) to visu-
alize holo-APP. The conditioned media of the same samples were resolved
on a 10% Bis-Tris NuPAge gel, with MES as running buffer and trans-
ferred to nitrocellulose membrane. The amyloid peptide was detected di-
rectly using mAb WO2 (ABETA GmbH). The quantity of conditioned me-
dium applied on the gel was normalized to the protein concentration of
the membrane pellet. Species-specific peroxidase-conjugated secondary
antibodies and the ECL method (Amersham Biosciences) were subse-
quently used. Quantification was done by densitometry of the autoradio-
grams using the NIH-image software.
Antibody-induced patching
Cultured neurons were first washed with PBS and incubated with 50 mM
2-mercaptoethanol for 5 min at 12 C. The cells were briefly washed with
CO2-independent MEM medium and incubated (45 min, 12 C) with pairs
of primary antibodies using: monoclonal anti–NH2-terminal APP (22c11;
Roche), chicken anti-BACE 1 and rabbit polyclonal anti-Thy1 (Biotrend).
After another brief washing the cells were incubated under the same con-JCB • VOLUME 167 • NUMBER 5 • 2004 960
ditions with fluorophore-coupled antispecies antibodies (AlexaFluor 488
and 568; Molecular Probes). Coverslips were fixed, mounted, and pic-
tures were acquired (objectives 40 /1.25, 63 /1.32) on a fluorescence
microscope (model DMIRE2; Leica) equipped with a digital camera (model
DC250; Leica) using the acquisition software (model Q550; Leica).
Quantification of copatching was performed as described previ-
ously (Harder et al., 1998; Ehehalt et al., 2003). In brief, 10 fields from
10 different pictures were taken. APP and BACE 1 clusters were converted
to colored circles (red for BACE 1 and green for APP). The degree of inter-
section among red and green circles was considered as “copatching” (in-
tersection  80%), “partial copatching” (intersection between 30% and
50%), “contact” (intersection between 0% and 30%), or random distribu-
tion. At least three independent experiments were performed for each cell
treatment. NIH image and Adobe Photoshop software were used to per-
form these analyses.
Online supplemental material
Fig. S1 shows that the absence of endogenous APP in DRMs does not de-
pend on the detergent used to isolate these microdomains (DRM isolation
on sucrose gradients). Fig. S2 shows the validation of the specificity of
DRMs fractionation from cultured neurons or mice brains through the use
of antibodies against flotilin 1, Prion protein for DRMs and transferrin re-
ceptor for non-DRMs. Fig. S3 shows the specificity of 22C11 anti-APP anti-
body in copatching experiments after epitope exposure with  -mercapto-
ethanol. Similar APP–BACE 1 copatching results are obtained with other
anti-APP antibodies without epitope exposure. Fig. S4 shows that APP is
not detected in DRMs of CHO cells constitutively expressing human APP.
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200404149/DC1.
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